Melinta Therapeutics Announces U.S. FDA Acceptance of Supplemental New Drug Application for BAXDELA® (delafloxacin) for the Treatment of Community-Acquired Bacterial Pneumonia
19. Juni 2019 07:30 ET
|
Melinta Therapeutics
~ Application Seeks to Expand Label to Include an Indication and Phase III Data for the Treatment of Adult Patients with Community-Acquired Bacterial Pneumonia (CABP) ~ ~ PDUFA Date Set for October...
Melinta Therapeutics to Present at Making a Difference in Infectious Diseases (MAD-ID) 2019 Annual Meeting
07. Mai 2019 07:30 ET
|
Melinta Therapeutics
MORRISTOWN, N.J., May 07, 2019 (GLOBE NEWSWIRE) -- Melinta Therapeutics, Inc. (NASDAQ: MLNT), a commercial-stage company focused on the development and commercialization of novel antibiotics to...
Melinta Therapeutics to Report First Quarter 2019 Financial Results on May 9, 2019
02. Mai 2019 16:30 ET
|
Melinta Therapeutics
MORRISTOWN, N.J., May 02, 2019 (GLOBE NEWSWIRE) -- Melinta Therapeutics, Inc. (NASDAQ: MLNT), a commercial-stage company focused on the development and commercialization of novel antibiotics to...
Melinta Therapeutics Announces Multiple Presentations at the 29th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)
08. April 2019 07:30 ET
|
Melinta Therapeutics
MORRISTOWN, N.J., April 08, 2019 (GLOBE NEWSWIRE) -- Melinta Therapeutics, Inc. (NASDAQ: MLNT), a commercial-stage company focused on the development and commercialization of novel antibiotics to...
Melinta Therapeutics Reports Fourth Quarter and Full-Year 2018 Financial Results
13. März 2019 16:00 ET
|
Melinta Therapeutics
~ Reports Revenue of $96.4 million, Including Net Product Sales of $46.6 million, for the Full-Year 2018 ~ ~ Net Product Sales of $14.6 million for the Fourth Quarter of 2018, up 32 Percent from...
Melinta Therapeutics to Report Fourth Quarter and Year-End 2018 Financial Results on March 13, 2019
05. März 2019 08:00 ET
|
Melinta Therapeutics
MORRISTOWN, N.J., March 05, 2019 (GLOBE NEWSWIRE) -- Melinta Therapeutics, Inc. (NASDAQ: MLNT), a commercial-stage company focused on the development and commercialization of novel antibiotics to...
Melinta Therapeutics Announces Closing of Initial $75 Million Vatera Convertible Loan Funding
25. Februar 2019 08:15 ET
|
Melinta Therapeutics
– Amendment to Deerfield Facility Agreement Becomes Effective – – John H. Johnson Appointed Permanent Chief Executive Officer – – Company to Report Fourth Quarter and Full Year 2018 Financial...
Melinta Therapeutics Appoints John Temperato President and Chief Operating Officer
23. Februar 2016 08:00 ET
|
Melinta Therapeutics
New Haven, CT, Feb. 23, 2016 (GLOBE NEWSWIRE) -- Melinta Therapeutics today announced that John Temperato has joined Melinta as President and Chief Operating Officer. Prior to joining Melinta,...
Melinta Therapeutics Secures up to $30 Million from Hercules Technology Growth Capital
09. Februar 2015 08:00 ET
|
Melinta Therapeutics
New Haven, Conn, Feb. 9, 2015 (GLOBE NEWSWIRE) -- Melinta Therapeutics announced today that it has entered into a
$30 million growth capital debt financing agreement with Hercules
Technology Growth...
Melinta Therapeutics Demonstrates Potent In Vitro Activity of New Antibiotic Class against Gram Negative ESKAPE Pathogens
08. September 2014 15:01 ET
|
Melinta Therapeutics
NEW HAVEN, Conn, Sept. 8, 2014 (GLOBE NEWSWIRE) -- Melinta Therapeutics today
provided an update on the Company's innovative ESKAPE Pathogen
Program. The ESKAPE Pathogen
Program leverages Melinta's...